Silver Book Fact

Savings associated with t-PA treatment for ischemic stroke patients

A $600 net savings is associated with each ischemic stroke patient treated with t-PA. In 2005, only 2% of all ischemic stroke patients received t-PA. If that percentage was increased to 4% the realized cost savings would be approximately $15 million. If increased to 20%, the savings would be around $74 million.

Demaerschalk B, Yip T. Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States. Stroke. 2005; 36(11): 2500-3. http://stroke.ahajournals.org/cgi/content/full/36/11/2500

Reference

Title
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States
Publication
Stroke
Publication Date
2005
Authors
Demaerschalk B, Yip T
Volume & Issue
Volume 36, Issue 11
Pages
2500-3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Beta-Blocker Treatment After A Heart Attack: Trends, 1996-2006  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Major cardiovascular event rates could be reduced by 80% simply by acting on known risk factors with therapies already shown to be effective.  
  • Using technologies as treatment for heart disease helps generate cost savings, including a total of $1930 annual savings per person, and a $1.5 billion increased tax revenue  
  • A major objective is to control blood pressure and preempt primary and secondary stroke. Assessing specific antihypertensive therapies will identify specific treatments that will lower blood pressure.